AstraZeneca PLC (AZN)
| Market Cap | 240.58B |
| Revenue (ttm) | 47.61B |
| Net Income (ttm) | 6.33B |
| Shares Out | 3.10B |
| EPS (ttm) | 2.03 |
| PE Ratio | 38.10 |
| Forward PE | 16.31 |
| Dividend | $1.45 (1.87%) |
| Ex-Dividend Date | Feb 22, 2024 |
| Volume | 2,971,948 |
| Open | 76.92 |
| Previous Close | 76.97 |
| Day's Range | 76.86 - 77.64 |
| 52-Week Range | 60.47 - 77.63 |
| Beta | 0.16 |
| Analysts | Buy |
| Price Target | 82.33 (+6.08%) |
| Earnings Date | Apr 25, 2024 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $82.33, which is an increase of 6.08% from the latest price.
News
AstraZeneca starts worldwide withdrawal of COVID vaccine
AstraZeneca has begun the worldwide withdrawal of its COVID vaccine - ending an era in which it saved millions of lives while being dogged by controversy.
AstraZeneca pulls its COVID-19 vaccine from the European market
LONDON — The pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled, according to the EU medicines regulator.
AstraZeneca to withdraw Covid vaccine worldwide, citing a drop in demand
Pharmaceutical giant AstraZeneca on Wednesday said it planned to withdraw its Covid-19 vaccine as demand for it has declined.
AstraZeneca withdraws COVID-19 vaccine
AstraZeneca said it's withdrawing its COVID-19 vaccine worldwide, with the company saying there's a surplus of available vaccines that are available.
AstraZeneca gets £3 billion valuation boost following global vaccine withdrawal
AstraZeneca has witnessed a significant increase in its market valuation, adding more than £3 billion as it announced the global withdrawal of its COVID-19 vaccine. The company's shares rose by 1.6 pe...
AstraZeneca to withdraw its COVID-19 vaccine globally as demand dips, rare side effects revealed
The pharmaceutical giant AstraZeneca said on Tuesday it is withdrawing its COVID-19 vaccine worldwide due to low demand and following reports that the vaccine caused rare side effects.
AstraZeneca to withdraw Covid vaccine worldwide, The Telegraph reports
Anglo-Swedish drugmaker AstraZeneca is withdrawing its Covid vaccine worldwide, The Telegraph reported on Tuesday.
Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau
HONG KONG--(BUSINESS WIRE)--Inocras Hong Kong, in partnership with Cancerinformation.com.hk Charity Foundation (CICF) and generously sponsored by AstraZeneca Hong Kong, is pleased to announce the laun...
Angle PLC Announces New Commercial Agreement with Large Pharma
ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies GUILDFORD, SURREY / ACCESSWIRE / May 3, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a ...
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca's CALQUENCE® (acalabrutinib) in combination with standard-of-care...
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Soci...
FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How
The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo...
FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'
WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting indu...
'A shadow of what I was': Dad who suffered brain injury days after getting COVID jab sues AstraZeneca
A dad who suffered a brain injury just days after receiving a British-developed COVID vaccine has told Sky News he would never have had the jab if he had known of the risk of rare but serious side eff...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant...
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06.
AstraZeneca Shares Jump Most Since 2020
Pascal Soriot, CEO of AstraZeneca, joins the Bloomberg Intelligence to discuss AstraZeneca earnings, along with regulatory and scientific updates. He spoke with Paul Sweeney and Molly Smith on Bloombe...
AstraZeneca CEO talks blowout earnings, global growth, new drugs, and pricing
AstraZeneca shares (AZN) revealed a first-quarter earnings beat on Thursday, posting revenue of $12.68 billion, a 19% year-over-year gain. In addition, the pharmaceutical giant has reiterated its full...
AstraZeneca Gets a Boost From Sales of Its Cancer Drugs
American depositary receipts (ADRs) of AstraZeneca (AZN) traded near their all-time high as the Anglo-Swedish pharmaceutical company had solid first-quarter demand for its cancer drugs.
AstraZeneca tops first-quarter revenue and profit expectations
AstraZeneca CEO Pascal Soriot outlines how the pharma giant's first-quarter results were boosted by demand for its rare blood disorder and oncology drugs.
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
ROCKVILLE, Md. , April 25, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innov...
AstraZeneca earnings beat expectations as steady drug sales boost revenues
AstraZeneca plc today, on April 25, announced its earnings report for the first quarter of FY24. Total Revenue increased by 19% to $ 12,679 million, driven by an 18% increase in product sales and cont...
AstraZeneca Earnings, Sales Beat Views
AstraZeneca reiterated its full-year guidance after posting first-quarter core earnings and sales above forecasts.
AstraZeneca CFO on Earnings, US Inflation Reduction Act, China Market
AstraZeneca Chief Financial Officer Aradhana Sarin discusses first-quarter earnings, implications of the US Inflation Reduction Act and the outlook for the company's commercial business in China. She ...